What’s Next? Five Things To Look Out For In November
GGB Awards And CPhI Kick Off Busy Month For Industry
European litigation, potential US generic launches and new CEOs are among the headlines in November – amid the ninth annual Global Generics & Biosimilars Awards, in Frankfurt.
You may also be interested in...
With growing interest in expanding the use of mRNA vaccines beyond COVID-19, the European Pharmacopoeia Commission has announced a new working party whose first task will be to develop a consolidated strategy on future standards for these vaccines and their components.
Teva has capitalized on a recent legal victory in the UK by claiming the first launch of a generic apixaban rival to BMS’ Eliquis.
While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.